2.93 USD
▼-0.07-2.33%
盘后 3.40 0.00%
2026-09-15
市值
$116.63M
市盈率
—
EPS
-2.58
股息率
—
52 周区间
2.23 – 5.38
成交量
171.10K
Beta
—
目标价
15.50
52W 低 2.2352W 高 5.38
价格走势
公司简介
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.